E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Fresh impact injuries of the limbs (Contusions, strains and sprains) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to show superior efficacy of Diclofenac Sodium 140 mg medicated plaster over Placebo plaster as assessed by absolute change of pain on movement from baseline Visit 1 (Day 1) to Visit 3 (Day 3) in the indication fresh impact injuries of the limbs. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the clinical trial are the evaluation of the trial drug's efficacy with reagrd to secondary efficacy variables and safety in comparison to Placebo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males or females, age range 18-60 years, outpatients. 2. Good general health. 3. Written informed consent. 4. Fresh impact injury of the limbs presented within 3 hours after injury. 5. The size of the visible traumatisation must be at least 25 cm2 and maximal 150 cm2 (in case of a muscle strain the area is assessed through palpation). 6. Pain assessment on movement by patient greater or equal 40 mm at baseline Visit 1 on a 100 mm VAS. |
|
E.4 | Principal exclusion criteria |
1. History of blood coagulation disorders. 2. History of asthma, COPD, hay fever and swelling of nasal mucosa. 3. Pregnancy or lactation period. 4. Women with childbearing potential without effective contraceptive methods. 5. Known allergy or hypersensitivity to: Diclofenac, paracetamol, acetylsalicylic acid, salicylic acid, other NSAIDs or cyclooxygenase 2-specific inhibitor (COXIB) or known intolerance (cutaneous or systemic) to any of the ingredients of the plaster, such as butylated methacrylate copolymer, copolymer acrylate vinyl acetate, PEG 12 stearate, sorbitan oleate. 6. Current skin disorders/open wounds in the area to be treated. 7. Gastric and intestinal ulcer. 8. Gastrointestinal, cerebrovascular or other active bleedings. 9. Evidence of liver, kidney or haematopoetic disorders. 10. Patients affected by rheumatoid arthritis or gout. 11. Known malignant diseases in the last 5 years. 12. Pre-treatment of injury. Previous cooling (ice, cooling spray) is authorised prior to screening . It is also allowed to cool the injury during the screening period until randomisation with a moist cloth and water at room temperature (no ice, no cooling spay). 13. Any patient, in the investigators opinion not considered suitable for enrolment. 14. Anticipated poor compliance by the patient. 15. Use of non-steroidal anti-inflammatory drugs, analgesics (e.g. acetyl salicylic acid, with the exception of paracetamol) or psychotropic agents within 3 days before trial participation or corticosteroids oral within 2 weeks or intravenous within 4 weeks before trial participation. 16. Use of glucosamine, chondroitine sulphate, diacerine, hyaluronic acids and bisposphonates in the last 4 weeks. 17. Participation in another clinical trial and/or treatment with an experimental drug within 4 weeks before participation in the trial. 18. Previous participation in this clinical trial. 19. Any relevant surgical treatment during the previous 2 months or planned during the trial. 20. Patient with a history of serious psychiatric disorders. 21. Abuse of alcohol, medicaments or illicit drugs. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Absolute change in pain on movement from baseline Visit 1 (Day 1) to Visit 3 (Day 3) (whil moving the arm or walking 5 steps on an even surface) assesed by patient on Visual Analogue Scale (VAS) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |